Recommendations for the use of WBC growth factors: American Society of Clinical Oncology clinical practice guideline update

TJ Smith, K Bohlke, GH Lyman, KR Carson… - Journal of Clinical …, 2015 - ascopubs.org
Purpose To update the 2006 American Society of Clinical Oncology guideline on the use of
hematopoietic colony-stimulating factors (CSFs). Methods The American Society of Clinical …

Research on the economics of cancer-related health care: an overview of the review literature

AJ Davidoff, K Akif, MT Halpern - JNCI Monographs, 2022 - academic.oup.com
We reviewed current literature reviews regarding economics of cancer-related health care to
identify focus areas and gaps. We searched PubMed for systematic and other reviews with …

G‐CSF utilization rate and prescribing patterns in United States: associations between physician and patient factors and GCSF use

G Barnes, A Pathak, L Schwartzberg - Cancer Medicine, 2014 - Wiley Online Library
Febrile neutropenia (FN) is a common complication among patients with chemotherapy‐
induced myelotoxicity and is associated with a number of negative outcomes including …

Meta-analysis and indirect treatment comparison of lipegfilgrastim with pegfilgrastim and filgrastim for the reduction of chemotherapy-induced neutropenia-related …

TC Bond, E Szabo, S Gabriel… - Journal of Oncology …, 2018 - journals.sagepub.com
Background Granulocyte colony-stimulating factors are effective at reducing the risk and
duration of neutropenia. The current meta-analysis compared the neutropenia-related …

Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population

AA Kawatkar, AJ Farias, C Chao, W Chen… - Supportive care in …, 2017 - Springer
Purpose The study objective was to evaluate chemotherapy treatment patterns and
incidence, cost, and resource utilization of febrile neutropenia-related hospitalization (FNH) …

Economic modeling for the US of the cost-efficiency and associated expanded treatment access of conversion to biosimilar pegfilgrastim-bmez from reference …

A McBride, W Wang, K Campbell, S Balu… - Journal of Medical …, 2020 - Taylor & Francis
Aims: For this economic analysis, we aimed to model:(1) the cost-efficiency of prophylaxis
with biosimilar pegfilgrastim-bmez for chemotherapy-induced (febrile) neutropenia (CIN/FN) …

[图书][B] Biosimilars and Interchangeable Biologics: Tactical Elements

SK Niazi - 2016 - books.google.com
Even very established companies have made mistakes when developing biosimilar
products. For example, not appreciating future threats to intellectual property caused a …

Real-world cost–effectiveness of primary prophylaxis with G-CSF biosimilars in patients at intermediate/high risk of febrile neutropenia

P Cornes, J Kelton, R Liu, O Zaidi, J Stephens… - Future …, 2022 - Taylor & Francis
Background: Real-world data suggests superiority of pegfilgrastim (PEG) over filgrastim (FIL)
in reducing the incidence of chemotherapy-induced febrile neutropenia (FN), probably …

Comparative study of adverse drug reactions associated with filgrastim and pegfilgrastim using the EudraVigilance database

S Rastogi, V Kalaiselvan, YA Bin Jardan, S Zameer… - Biology, 2022 - mdpi.com
Simple Summary The most commonly reported adverse drug reactions (ADRs) related to
filgrastim (FIL) and pegfilgrastim (PEG-F) were obtained and analyzed from the European …

New G-CSF agonists for neutropenia therapy

J Hoggatt, LM Pelus - Expert opinion on investigational drugs, 2014 - Taylor & Francis
Introduction: Granulocyte colony-stimulating factor (G-CSF; filgrastim) and its pegylated form
(pegfilgrastim) are widely used to treat neutropenia associated with myelosuppressive …